Abstract:ObjectiveTo investigate the impact of the change in anti-hepatitis B virus (HBV) therapy indication on treatment rate and the features of the population requiring treatment. MethodsThe treatment-nave patients with chronic hepatitis B (CHB) in the China Registry of Hepatitis B (CR-HepB) database were selected as subjects, and related demographic, virological, hematological, and biochemical data were collected. The Mann-Whitney U test was used for comparison of non-normally distributed continuous data between two groups, and the Kruskal-Wallis H test was used for comparison between multiple groups; the chi-square test or the Fisher’s exact test was used for comparison of categorical data between groups. ResultsA total of 3640 treatment-nave CHB patients were included in this study, among whom 64.4% were male, 68.7% had an age of 30-59 years, and 46.8% had an indeterminate clinical stage. According to the 2015 and 2019 editions of Guidelines for the prevention and treatment of chronic hepatitis B and the 2022 edition of expert consensus, the number of patients who had the indication for antiviral therapy was 625(17.2%), 1333(36. 6%), and 2890(79.4%), respectively. The number of patients requiring treatment was increased by 1557 according to the 2022 edition of expert consensus, among whom 1424(91.5%) met the treatment threshold of alanine aminotransferase (ALT) ＞30 U/L for male patients or ALT ＞19 U/L for female patients. The additional patients requiring treatment according to the 2022 edition of expert consensus had significantly higher levels of ALT and HBV DNA and significantly lower scores of APRI and FIB-4 than the additional patients requiring treatment according to the 2019 edition of Guidelines (all P＜0.05). ConclusionThe expansion of antiviral therapy indications for CHB may significantly increase the proportion of CHB patients receiving antiviral treatment and help mild CHB patients at the risk of disease progression to receive timely treatment and achieve the improvement in long-term prognosis.

Advances and new strategies for the treatment of chronic hepatitis B

New advances in drug therapy of chronic hepatitis B infection

Advances in Hepatitis B Treatment

Current trends and advances in antiviral therapy for chronic hepatitis B

Advances in treatment and prevention of hepatitis B

Advances in determining new treatments for hepatitis B infection by utilizing existing and novel biomarkers

Emerging Antivirals for the Treatment of Hepatitis B

Progress in Nucleoside and Nucleotide Analogue Therapy for Chronic Hepatitis B

Current treatment of chronic hepatitis B: Clinical aspects and future directions

Research advances in cytokines in the treatment of chronic hepatitis B

Antiviral treatment standards for hepatitis B: An urgent need for expansion

Research Progress in Combination Therapy with Pegylated Interferon and Nucleos(t)ide Analogues in Treatment of Chronic Hepatitis B

Perspective on Emerging Therapies to Achieve Functional Cure of Chronic Hepatitis B

Effect of the Change in Antiviral Therapy Indication in Increasing the Treatment Rate of Chronic Hepatitis B

Emerging drugs for the treatment of hepatitis B

Advances in drugs and biotechnology targeting hepatitis B virus cccDNA

Progress in the antiviral treatment of HBV-related cirrhosis

Management of chronic hepatitis B: experience from China

Development of novel therapeutics for chronic hepatitis B

Novel mechanistic insights – A brand new Era for anti-HBV drugs

[Recent Advances in the Treatment of Hepatitis C in 2016].